PKI News and Press, PerkinElmer Inc. From 10/28/20

Revenue of $964.0 million; 36% reported growth; 34% organic growth GAAP EPS from continuing operations of $1.57; Adjusted EPS of $2.09 PerkinElmer, Inc . (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial resu...

The best sectors to focus your attention on now. The highest-rated stocks worth adding to your watch list. Why high-volatility ahead of elections could create a great buy opportunity. For further details see: If Stocks Tumble On Election Worries, Here Are The Top Stocks ...

PerkinElmer (NYSE:PKI) is scheduled to announce Q3 earnings results on Wednesday, October 28th, after market close.The consensus EPS Estimate is $1.49 (+40.6% Y/Y) and the consensus Revenue Estimate is $837.16M (+18.4% Y/Y).Over the last 2 years, PKI has beaten EPS estimates 75% of the time a...

PerkinElmer (PKI) announces CE Mark certification of its PKamp Respiratory SARS-CoV-2 RT-PCR Panel that differentiates between SARS-CoV-2, influenza A viruses, influenza B viruses and respiratory syncytial virus ((RSV)) in a single assay from a single nasopharyngeal, oropharyngeal or nasal sw...

Company’s latest test enables differential diagnosis between COVID-19, flu and RSV infection PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnosti...

PerkinElmer (PKI) declares $0.07/share quarterly dividend, in line with previous.Forward yield 0.22%Payable Feb. 12; for shareholders of record Jan. 22; ex-div Jan. 21.See PKI Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: PerkinElmer declares $0.07 div...

Findings shared on open data portal to help in global pursuit of drug repurposing candidates for COVID-19 PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that a research team at the National Center for Advancin...

Abcam has filed to raise capital in a U.S. IPO. The firm sells or licenses reagents and antibodies to biopharmaceutical research organizations worldwide. While the firm has seen a recent contraction in revenue due to Covid-19, I suspect this is temporary; ABCM is well position...

The table in the release was incorrect. The corrected table should read: PerkinElmer, Inc: (1) amounts may not sum due to rounding The updated release reads: PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020 PerkinE...

PerkinElmer, Inc. (NYSE: PKI) , a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 35% and 33%, respectively, for the third quarter ended October 4, 2020. The strong revenue ...